Citations

Clear

55 citation(s) found for "Sengupta, S".

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda, William G. , Dorritie, Kathleen , Gauthier, Jordan , Nath, Rajneesh, Kipps, Thomas J. , Riedell, Peter A. , Eradat, Herbert A., Kharfan‐Dabaja, Mohamed A. , Shah, Nirav N. , Solomon, Scott R., Stephens, Deborah M., Ermann, Daniel A., Arnason, Jon , Deol, Abhinav , Feldman, Tatyana , Ghosh, Monalisa , Tuazon, Sherilyn A., Perna, Serena K., Ou, San-San, Ananthakrishnan, Revathi , Rane, Neha, Papp, Eniko, Ansari, Sahar , Thompson, Ethan G., Okal, Abood, Peiser, Leanne, Chen, Yizhe , Sengupta, Sanhita , Wang, Jixian , Wierda, William G. , Dorritie, Kathleen , Kenderian, Saad S. , Kharfan-Dabaja, Mohamed A , Shah, Nirav N , Deol, Abhinav , Ma, Shuo , Schuster, Stephen J , Gergis, Usama , Vose, Julie , Soumerai, Jacob D , Besien, Koen van , Chen, Yizhe , Sengupta, Sanhita , Ray, Pradipta Ranjan , Siddiqi, Tanya , Kipps, Thomas J , Riedell, Peter A , Nath, Rajneesh , Eradat, Herbert, Stephens, Deborah M. , Andreadis, Charalambos Babis , Ma, Shuo , Schuster, Stephen J. , Vose, Julie M. , Soumerai, Jacob D. , Tuazon, Sherilyn A. , Perna, Serena , Ou, San‐San , Papp, Eniko , Ansari, Sahar, Siddiqi, Tanya

Mayo Clinic

Blood Journal | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033565 | PMID 42520199 Get It

Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)
Ζεκερίδου, Αναστασία , Gutman, Jonathan, Lowe, Mallory, Eggmann, Sadie, McKeon, Andrew, Pittock, Sean J., Yi, Jessica J., Newsome, Scott D., Chou, Justin, Blarcom, Tom Van, Han, Xue, Sun, John, Sengupta, Shouvonik , Tooker, Ryan, Mehta, Aditi, Grayson, Dena , Gehchan, N., Piquet, Amanda L. , Gergis, Usama , Gutman, Jonathan A. , Kenderian, Saad S. , McKeon, Andrew , Pittock, Sean J. , Rakočević, Goran , Dalakas, Marinos C.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217905 Get It

Abstract PS3-07-23: Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
Chapman, J. W., Bayani, Jane , SenGupta, S., Bartlett, J. M. S., Piper, T., Quintayo, M. A., Virk, Shakeel , Goss, P. E., Ingle, J. N., Ellis, M. J., Sledge, G. W., Budd, G. T., Ansari, R. H., Tozer, Richard , D'Souza, D. P., Chalchal, H., Spadafora, S., Stearns, V., Perez, E. A., Gelmon, K. A., Whelan, T. J., Elliott, C., Shepherd, L. E., Chen, B. E., Taylor, K. J., Whelan, Timothy J. , Bartlett, J. M. S., Quintayo, Mary Anne , Ingle, J. N., Budd, G.T., Rabaglio, Manuela , D’Souza, David , Chalchal, H., Stearns, Vered , Shepherd, Lois E. , Chen, B. E., Taylor, K. J., Whelan, Timothy J

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-07-23-PS3-07-23

10.1158/1557-3265.sabcs25-ps3-07-23 Get It

Abstract Background: Survivor plots permit adjustment by baseline demographics and clinical characteristics; log-normal survival analysis may be more robust than a Cox model under departures from model assumptions. We depicted distant disease-free survival (DDFS) for statistically standardized quantitated ER, PgR, and HER2. Methods: We utilized CCTG MA.27 (NCT00066573), an adjuvant phase III trial of exemestane versus anastrozole in postmenopausal women with ER+ and/or PgR+ tumours. IHC ER, PgR, and HER2 HSCORE were centrally assessed by machine image quantitation, and statistically standardized to mean of 0, standard deviation (SD) of 1 following Box-Cox variance stabilization transformations of square for ER, natural logarithm (ln) and square root for PgR, and ln for HER2. For the ln transformation, 0.1 was added to 0 HSCOREs for a stable transformation. The primary endpoint was DDFS at the longest trial follow-up of 4.1 years. For log-normal survival analysis, ln(time) is a linear function of covariates and had a normal distribution; the Cox models were log-linear for covariates. Survival was depicted with log-normal and Cox survivor plots adjusted at the means of age, T and N stage, grade, lymphovascular invasion, treatment, and baseline patient demographics. We examined ER and PgR ASCO/CAP cut-points at (0; >0), HER2 cut-points at (IHC 0, 0 stain; IHC 0, (0,10%] stain; IHC 1+; IHC 2+; IHC 3+), and ER/PgR/HER2 standardized cut-points at standard deviations about mean of 0 (<-1; (-1,0]; (0,1]; >1). P was based on the likelihood ratio criterion (∼Χ2 (1)) for the addition of ER/PgR/HER2 to the model of baseline covariates, and had nominal significance if P<0.05. Log-normal and Cox multivariable regressions with unstandardized and standardized categorical, and continuous, ER, PgR, and HER2 were adjusted by baseline covariates; 2-sided Wald tests had nominal significance if P<0.05. Results: Of 7576 MA.27 patients, 2325 patients had quantitated image analysis assessments for ER, PgR, and HER2; 113 of 2325 (4.9%) patients experienced a DDFS event during follow-up. Multivariable log-normal survival analysis indicated DDFS was significantly longer for patients with T1 (p=0.01), N0 (p=.002), and grade 1/2 tumors (p=0.01); similar significance levels were found with a Cox model. Log-normal survivor plots were smooth, while Cox survivor plots were step-wise discontinuous at events. Adjusted log-normal survivor plots indicated similar 5-year DDFS for patients by standardized ER categories (p=0.43): 95.4% for those with ER <-1.0 (n=401); 95.8%, for (-1.0,0.0] (n=737); 96.1%, for (0.0,1.0] (n=737); and 96.4%, for >1.0 (n=450). The log-normal standardized PgR survivor plots indicated patients had significantly different 5-year DDFS (p<.001) by categories, with both ln and square root transformations of HSCORE: with a ln transformation, 93.7% for <-1.0 (n=607); 95.4%, for (-1.0,0.0] (n=390); 96.8%, for (0.0,1.0] (n=826); and 97.8%, for >1.0 (n=502). Patients had similar 5-year DDFS by standardized HER2 categories (p=0.71): 96.2% for <-1.0 (n=83); 96.0%, for (-1.0,0.0] (n=1201); 95.9%, for (0.0,1.0] (n=527); and 95.7%, for >1.0 (n=514). In full fit multivariable log-normal survival analyses, DDFS was not significantly different for ER (p=0.51-0.89) and HER2 (p=0.12-0.98); higher PgR was associated with significantly better DDFS (p=0.01 to <.001). Adjusted Cox survival analyses had similar results. Conclusions: Survivor plots adjusted for baseline demographic and clinical characteristics provided similar indications of significance for standardized ER, PgR, and HER2 as those seen in multivariable models with both log-normal and Cox survival analyses. Higher PgR was associated with significantly better DDFS. Citation Format: J. W. Chapman, J. Bayani, S. SenGupta, J. M. S. Bartlett, T. Piper, M. A. Quintayo, S. Virk, P. E. Goss, J. N. Ingle, M. J. Ellis, G. W. Sledge, G. T. Budd, M. Rabaglio, R. H. Ansari, R. Tozer, D. P. D'Souza, H. Chalchal, S. Spadafora, V. Stearns, E. A. Perez, K. A. Gelmon, T. J. Whelan, C. Elliott, L. E. Shepherd, B. E. Chen, K. J. Taylor. Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-07-23.
Current and future use of artificial intelligence in valvular heart disease imaging
Sengupta, Partho P. , Poterucha, Timothy J. , Pezel, Théo , Tsang, Teresa S.M. , Poterucha, Timothy, Poterucha, Timothy Joseph , Cosyns, Bernard

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | December 5, 2025 | Volume: 27 | Issue: 2 | Pages: 319-329

10.1093/ehjci/jeaf348 | PMID 41355285 Get It

Abstract Valvular heart disease (VHD) remains significantly underdiagnosed and undertreated. This review examines an artificial intelligence (AI)-enhanced ‘spoke–hub–node’ care model designed to improve the early detection, risk stratification, and treatment of VHD. In this model, AI tools—such as automated ECG interpretation, digital stethoscopes, and point-of-care ultrasound—facilitate decentralized screening and referral for cardiac imaging at the community level. During the transition from outpatient settings to tertiary care centres, AI-integrated echocardiography, cardiac tomography, and magnetic resonance imaging facilitate advanced diagnostic evaluation and inform procedural planning. We review emerging innovations that can enhance this model of care delivery—including unsupervised machine learning to uncover novel VHD phenotypes, generative AI for automated reporting, the use of digital twins to simulate interventions, and the integration of multiple AI agents to support heart team meetings. These advances are followed by the emerging use of AI in robotic transoesophageal and intracardiac echocardiography, as well as in fusion fluoroscopy imaging, to guide valve interventions. While outlining the challenges inherent in this rapidly evolving field, the review’s central contribution is its vision to connect the continuum—from AI-enabled community screening to personalized, image-guided therapies at tertiary care centres—offering a scalable and equitable model for VHD care.
TMIC-83. Targeting Lipid Metabolism in GBM: A Systems Biology Strategy to Overcome Treatment-Resistant Persister Cells and Their Myeloid Cell-Mediated Support
Chakraborty, Avirup , Yang, Changlin , Feier, Diana , Silver, Aryeh , Searl, Nyla, Anica, Miruna, Pittu, Avinash, West, Illeana, Sobanjo, Olusegun O., Hodge, Ethan, Engelbart, Mia, Sengupta, Srabasti, Thomas, Nagheme, Rahman, Maryam, Mitchell, Duane A. , Sarkisian, Matthew R. , Chakraborty, Avirup , Feier, Diana, Sengupta, Srabasti, Roemeling, Christina A. Von , Huang, Jiangping, Harrison, Jeffrey K. , Deleyrolle, Loic P.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v464-v464

10.1093/neuonc/noaf201.1838 Get It

Abstract INTRODUCTION Glioblastoma (GBM) contains metabolically distinct cell lineages: treatment-sensitive cells (TSCs) dependent on glycolysis and treatment-resistant persister cells (TRPCs) reliant on lipid metabolism. Our integrative systems biology approach, combining spatial multi-omics and targeted analyses, uncovers lipid acquisition in TRPCs as a pivotal driver of GBM progression which is supported by a retrospective study of statin-treated patients, providing clinical evidence for the therapeutic potential of targeting lipid metabolism in GBM patients stratified based on high TRPC signatures. METHODS We applied spatial transcriptomics and proteomics combined with 3D reconstruction of the tumor microenvironment to map TRPC- and TSC-enriched regions. Immunohistochemically stained tissues were analyzed using CellProfiler and our custom SNAQ algorithm for single-cell neighborhood analysis. Lipid transfer from Tumor-Associated Myeloid Cells (TAMCs) to TRPCs was tracked via flow cytometry, holotomography, and time-lapse imaging. Genetic and pharmacological targeting of CCR2, CSF1R, and FABP3 was performed in vitro and in vivo. Finally, a retrospective analysis of 4,085 GBM patients assessed the impact of statin treatment in relation to TRPC signatures. RESULTS TRPCs exploit recruited TAMCs to acquire lipids, supporting their survival and immune evasion. These interactions are mediated by CCL2/7–CCR2 and CSF1–CSF1R signaling. Disruption of TRPC-TAM lipid homeostasis significantly remodeled the immune microenvironment, reduced tumor growth, and extended survival in preclinical models. Patients with high TRPC signatures typically had poor outcomes; however, retrospective analysis revealed that statin treatment was associated with improved survival in this subgroup. These findings position lipid trafficking as a metabolic vulnerability in GBM and highlight the therapeutic relevance of targeting TRPC–TAMC interactions. CONCLUSION Our study reveals lipid trafficking to TRPCs as a key mechanism driving GBM progression. Targeting TAMC-mediated lipid transfer disrupts immune suppression and tumor growth. Transcriptomic profiling may guide patient stratification, identifying those likely to benefit from lipid metabolism-targeted therapies such as statins.
EXTH-109. Overexpressing glucose transporters to enhance CAR-T cell metabolic programming to treat glioblastoma
Sengupta, Srabasti, Yamaguchi, Adriana, West, Illeana, DeYoung, Chloe , Rugger, Niccolò A, Jin, Dan , Thomas, Nagheme, Feier, Diana , Silver, Aryeh , Chakraborty, Avirup , Rahman, Maryam, Mitchell, Duane A. , Sengupta, Srabasti, Yamaguchi, Adriana, Tao, Haipeng , Chauhan, Anjali , Feier, Diana, Chakraborty, Avirup , Huang, Jianping, Deleyrolle, Loic P.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v365-v365

10.1093/neuonc/noaf201.1442 Get It

Abstract INTRODUCTION Glioblastoma (GBM) is a brain cancer known for its complex tumor microenvironment and ability to reprogram glucose metabolism and evade host immune responses. CAR-T cell therapy has attracted considerable attention due to its potential for high specificity and efficacy across various cancer types. However, its success in GBM has been limited due to the unique and hostile metabolic landscape of the tumor microenvironment. GBM tumor cells exhibit enhanced aerobic glycolysis, resulting in elevated glucose consumption. This restricts glucose availability for T cells, impairing activation and anti-tumor response. In our study, we enhanced the tumoricidal activity of CD70 CAR T-cells by overexpressing the glucose transporters GLUT1 and GLUT3, thereby improving their metabolic fitness and enabling them to overcome tumor-induced glucose deprivation. METHODS The CD70 CAR T-cell glucose metabolic pathway was modulated via glucose transporter overexpression. The efficacy and safety of metabolically modified CD70 CAR T-cells was investigated in in vitro and in vivo platforms. RESULTS GLUTs overexpression does not negatively affect T-cell differentiation and function but improves glucose consumption and intra-tumoral T-cell trafficking. We then used CD70 CAR-T platform and overexpress GLUT1 and GLUT3 to engineer T-cells. GLUT overexpression provided metabolic advantage to CD70CAR T-cells, which showed enhanced activation and cell avidity when co-cultured with GBM cells in both glucose enriched and restricted conditions. The metabolic modifications regulate CAR T-cell efficacy by enhancing intra-tumoral trafficking and persistence, followed by improved anti-tumor response and survival in mice. The lack of significant alterations in body weight and organ morphology in mice receiving GLUT-overexpressing CD70 CAR T-cells suggests that the adoptive transfer of these metabolically enhanced T cells does not elicit toxicity, thereby demonstrating a favorable safety profile during treatment. CONCLUSION Our study demonstrates development of immunotherapeutic strategies by incorporating core principles of tumor and immune cell metabolism, thus providing evidence that targeting immune-metabolic pathways is a potential approach to treat brain tumor.
Abstract 4371463: Cuffless Blood Pressure Monitoring Using a Novel Wrist-Worn Photoplethysmography Device: Validation Against Intra-Arterial Blood Pressure
Sosin, Benjamin, Sanyal, Alodeep, Mbouombouo, Benjamin, Banerjee, Nilanjan , Sengupta, Indranil , Cruz, Jessica, Asirvatham, Sam, Banerjee, Nilanjan, Sen-Gupta, Indranil, Kowlgi, Gurukripa N.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4371463 Get It

Background: Cuffless blood pressure (BP) monitoring devices with the ability to continuously and noninvasively collect data could transform the screening and management of hypertension. While some wearable devices can estimate BP, their accuracy and reliability remain limited. Objective: To evaluate the feasibility of using a wrist-worn photoplethysmography (PPG) device (Lifeleaf®) in combination with a supervised learning algorithm to infer clinically useful BP measurements. Methods: A total of 87 patients undergoing electrophysiology procedures were enrolled (Table 1). Time-synchronized BP data from an intra-arterial line served as the reference. These data were divided into (1) a training set to develop a convolutional neural network (CNN) and (2) a testing set to assess the algorithm’s predictive performance. Data from 60 patients were used to train the model, and the remaining 27 patients were used for validation. Results: Data from 81 of 87 patients were included in the final analysis. The mean age was 63.6 ± 10.5 years, and 69.1% were male. A total of 6,977 paired PPG and arterial BP readings were analyzed. The mean absolute deviation for systolic BP was 13.08 ± 17.22 mm Hg, and for diastolic BP, 8.42 ± 10.56 mm Hg. Subgroup analysis revealed reduced correlation in patients with BP >140/90 mm Hg, likely due to fewer training samples in this range. Conclusion: This study demonstrates the feasibility of extracting clinically meaningful BP measurements from a PPG device using a supervised learning algorithm. The use of arterial line BP as the reference standard adds methodological rigor. Future work will focus on enhancing model performance, particularly in the hypertensive cohort.
Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study
Lass, Jonathan H. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Beck, Roy W., Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Baratz, Keith H. , Hardtke, Elainey, Treichel, Emily J., Hood, Christopher , Nallasamy, Nambi , Verkade, Angela , Jones, Kristin, Shapiro, Jeremy N. , Leavy, Lisa, Sinkey, Chris, Tenkman, Lawrence R., Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Coonfield, Kristy, Vislisel, Jesse M., Sharma, Yogi, Young, Angela M. , Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Phillips, Paul, Maloney, Charlene, Jun, Albert S. , Maria, Christina, Boyce, Michelle, Kam, Yong, Crosser, Vicki, Chen, Jessica , Straiko, Michael D., Bauer, Alex, Croasdale, Christopher, Brown, Gayle Waldheim, Veldman, Peter B., Evans, Que, Majmudar, Parag A., Epstein, Rachel , Vaidya, Neal, Rosselson, Marie, Nykaza, Jim, Jurkunas, Ula V., Venkateswaran, Nandini, Cheung, Michael K., Ayres, Brandon D. , Haught, Drew Monteleone, Prasad, Elizabeth, Toti, G, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Hardten, David R., Reeves, Sherman, Dreyer, Allison, Mack, Megan, Hamill, M. Bowes , Nguyen, Jessica, Koo, Ellen, Stanfield, Ryan, Greenwood, Michael, Ernst, L, Messer, Brooke, Risbrudt, Nick, Stofferahn, Seth, Saville, Alyson, Castaneda, Leslie, Torres, Nidia, Potts, Luke B. , Alexander, Jamie, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Buckman, Natalie, Ansin, Amy, Clover, Jameson , Pivoney, Charles, Vizzerra, Anthony, Elbanhawy, Lindsey, Mullins, Monica, Statz, Brianne, Fout, Elizabeth, Drury, Donna, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Szczotka-Flynn, Loretta, Richards, Leslie, Raghupathy, Sangeetha, Spruill, Rashad, Bauza, Colleen, Kollman, Craig, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Lê, Jimmy T. , Redford, Maryann , Arafah, Baha M. , Greiner, Mark, Johnson, Paula C, Keeler, D. K., Monnier, Vincent M. , Titus, Michael, Verdier, David, Soper, Mark, Velhuisen, Paul Van, Hawkins, Barbara S., Macsai, Marian S., Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dawson, Lauren, Dingess, Ryan, Madere, Mark, Sengupta, Pratim , Wadleigh, Garth, Greiner, Mark A. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Hood, Christopher, Sáles, Christopher S. , Sinkey, Chris, Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Young, Angela, Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Srikumaran, Divya S. , Daoud, Yassine J. , Eghrari, Allen Omid , Ali, Muhammad , Croasdale, Christopher, Brown, Gayle Waldheim, Epstein, Rachel H. , Vaidya, Neal, Jurkunas, Ula V. , Cheung, Michael, Prasad, Elizabeth, Toti, Gwen, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Reeves, Sherman, Dreyer, Allison, Mack, Megan, Nguyen, Jessica, Greenwood, Michael, Messer, Brooke, Saville, Alyson, Omar, Ahmed F. , Castaneda, Leslie, Torres, Nidia, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Schmidt, Gregory A. , Lass, Jonathan, Lass, Jonathan, Price, Marianne O. , Szczotka-Flynn, Loretta, Richards, Leslie, Bauza, Colleen, Beck, Roy W. , Kollman, Craig, McCarthy, Chris, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Greiner, Mark, Johnson, Paula, Titus, Michael, Verdier, David, Soper, Mark, Aleppo, Grazia , Bateman-House, Alison , Tu, Elmer Yuchen , Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dingess, Ryan, Sengupta, Paromita

Mayo Clinic

JAMA Ophthalmology | October 17, 2025 | Volume: 143 | Issue: 12 | Pages: 1053

10.1001/jamaophthalmol.2025.4261 | PMID 41105099 Get It

Importance The effect of cornea donor diabetes on endothelial cell density (ECD) and morphometry after Descemet membrane endothelial keratoplasty (DMEK) is not known. Objective To determine whether endothelial cell loss (ECL) and morphometric changes 1 year after successful DMEK are related to cornea donor’s diabetes status. Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2024 at 28 US clinical sites (46 surgeons) and 13 eye banks. Included in the trial were the eyes of recipients (some of whom received tissue from donors without diabetes and others who received tissue from donors with diabetes) who underwent successful DMEK, primarily for Fuchs endothelial corneal dystrophy, and had at least 1 analyzable postoperative endothelial image. Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure to achieve an approximate 2:1 distribution. Main Outcomes and Measures ECD, ECL, coefficient of variation in cell area (CV), and percentage of hexagonal cells (HEX) at 1 year from eye bank and postoperative specular central endothelial images. Results A total 1274 eyes of 982 recipients (mean [SD] age, 70 [8] years; 569 female [57.9%]; 816 [64.1%] with tissue from donors without diabetes and 458 [35.9%] with tissue from donors with diabetes) were included in the study. Preoperatively, mean (SD) central ECD in tissue from donors without diabetes and with diabetes were 2676 (290) cells/mm 2 and 2671 (286) cells/mm 2 , respectively. At 1 year, mean (SD) ECL was 28.3% (16.1%) and 28.0% (17.0%), in the donor groups without and with diabetes, respectively (adjusted mean difference = −0.4%; 95% CI, −2.3% to 1.4%), resulting in a mean (SD) 1-year ECD of 1927 (498) cells/mm 2 and 1920 (496) cells/mm 2 , respectively (adjusted mean difference = 10 cells/mm 2 ; 95% CI, −36 to 56; P = .95). No difference in ECD at 1 year associated with diabetes severity was noted ( P = .97). Mean (SD) CV did not differ at 1 year between the 2 groups of eyes (31.5% [4.1%] vs 31.4% [4.1%]; adjusted mean difference = −0.4%; 95% CI, −0.9% to 0.1%; P = .51), and mean (SD) HEX did not differ at 1 year between the 2 groups of eyes (57.7% [5.8%] vs 57.2% [5.8%]; adjusted mean difference = 0.1%, 95% CI, −0.8% to 0.9%; P = .33). Conclusions and Relevance This randomized clinical trial found that ECL and morphometry 1 year after DMEK were not affected by cornea donor diabetes status. With comparable 1-year graft success with tissue from donors with and without diabetes demonstrated in this trial, these findings support the use of corneas from donors with diabetes for endothelial keratoplasty procedures. Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate
Price, Francis W. , Szczotka‐Flynn, Loretta , Bauza, Colleen , Reed, Zachariah W., Arafah, Baha M. , Greiner, Mark A. , Johnson, Paula, Keeler, Devon B., Pramanik, Sudeep, Soper, Mark, Terry, Mark A., Titus, Michael S. , Verdier, David D. , Kollman, Craig, Lass, Jonathan H. , Lass, Jonathan H., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lynn, A. G., Cole, Shawna, Phelps, Derek, Baratz, Keith H. , Hardtke, Elainey, Treichel, Emily J., Hood, Christopher , Nallasamy, Nambi , Verkade, Angela , Jones, Kristin, Shapiro, Jeremy, Leavy, Lisa, Sinkey, Chris, Tenkman, Lawrence R., Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Coonfield, Kristy, Vislisel, Jesse M., Sharma, Yogi, Young, Angela M. , Schoenberg, Evan, Kelly, Sharra, Huffman, James L. , Sears, Melinda, Stone, Merisa, Phillips, Paul, Maloney, Charlene, Jun, Albert S. , Maria, Christina, Boyce, Michelle, Kam, Yong, Crosser, Vicki, Chen, Jessica , Straiko, Michael D., Bauer, Alex, Croasdale, Christopher, Brown, Gayle Waldheim, Veldman, Peter B., Evans, Que, Majmudar, Parag A., Epstein, Rachel , Vaidya, N. N., Nykaza, Jim, Venkateswaran, Nandini, Ayres, Brandon D. , Haught, Drew Monteleone, Prasad, Elizabeth, Toti, Gwen, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark D., Hardten, David R., Reeves, Sherman W., Dreyer, Allison, Mack, Megan, Hamill, Mark, Nguyen, Jessica , Stanfield, Ryan, Greenwood, Michael , Ernst, Lindsay, Risbrudt, Nick, Saville, Alyson, Castaneda, Leslie, Torres, Nidia, Potts, Luke B. , Alexander, Jamie, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Buckman, Natalie, Ansin, Amy, Clover, Jameson , Pivoney, Charles, Vizzerra, Anthony, Elbanhawy, Lindsey, Mullins, Monica, Statz, Brianne, Fout, Elizabeth, Drury, Donna, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Richards, Leslie, Raghupathy, Sangeetha, Spruill, Rashad, Bauza, Colleen, Beck, Roy, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann , Lê, Jimmy T. , Redford, Maryann , Arafah, Baha, Greiner, Mark, Keeler, Devon, Monnier, Vincent M. , Titus, Michael, Verdier, David, Velhuisen, Paul Van, Hawkins, Barbara S., Macsai, Marian S., Patel, Sanjay, Mian, Shahzad I. , Pramanik, Sudeep , Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dawson, Lauren, Dingess, Ryan, Madere, Mark, Wadleigh, Garth, Price, Marianne O. , Mian, Shahzad I. , Patel, Sanjay V. , Pramanik, Sudeep, Titus, Michael S., Beck, Roy W. , Lass, Jonathan H., Group, Diabetes Endothelial Keratoplasty Study, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Hardtke, Elainey, Hood, Christopher, Shapiro, Jeremy, Sáles, Christopher S. , Leavy, Lisa, Gordon, DJ, Fox, Jenni, Coonfield, Kristy, Young, Angela, Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Srikumaran, Divya S. , Daoud, Yassine J. , Eghrari, Allen Omid , Ali, Muhammad , Crosser, Vicki, Croasdale, Christopher, Brown, Gayle Waldheim, Evans, Que, Epstein, Rachel H. , Nykaza, Jim, Jurkunas, Ula V. , Cheung, Michael, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Mack, Megan, Hamill, M. Bowes, Nguyen, Jessica, Koo, Ellen H. , Stanfield, Ryan, Risbrudt, Nick, Saville, Alyson, Omar, Ahmed F. , Castaneda, Leslie, Torres, Nidia, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Schmidt, Gregory A. , Elbanhawy, Lindsey, Statz, Brianne, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Richards, Leslie, Spruill, Rashad, Bauza, Colleen, Beck, Roy, McCarthy, Chris, Reed, Zachariah, Arafah, Baha, Greiner, Mark, Titus, Michael, Verdier, David, Velhuisen, Paul Van, Aleppo, Grazia , Bateman-House, Alison , Tu, Elmer Yuchen , Patel, Sanjay, Price, Francis, Terry, Mark, Sell, David, Barton, Glenn, Das, Pravamaya, Dingess, Ryan, Madere, Mark, Sengupta, Partha Pratim , Wadleigh, Garth

Mayo Clinic

JAMA Ophthalmology | October 17, 2025 | Volume: 143 | Issue: 12 | Pages: 1043

10.1001/jamaophthalmol.2025.4253 | PMID 41105094 Get It

Importance If the success of Descemet membrane endothelial keratoplasty (DMEK) is not affected by whether the donor has diabetes, then the donor pool should expand. Objective To determine whether the 1-year DMEK success rate is affected by the presence of diabetes in the donor. Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2025 at 28 clinical sites (46 surgeons), with donor corneas provided by 13 eye banks in the US. Included in the study were individuals undergoing low to moderate risk DMEK (95% for Fuchs endothelial corneal dystrophy). Study data were analyzed from April to September 2025. Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure (comparable with randomization) to achieve an approximate 2:1 distribution, respectively. Main Outcomes and Measures Graft success at 1 year Results A total of 1097 individuals (1421 study eyes; median [IQR] age, 71 [66-76] years; 631 female [57.5%]) were included in the study. The 1-year cumulative probability of graft success was 96.3% (95% CI, 95.0%-97.5%) among 912 study eyes (64.2%) receiving tissue from donors without diabetes and 97.1% (95% CI, 95.5%-98.4%) among 509 study eyes (35.8%) receiving tissue from donors with diabetes (difference between groups = 0.7 percentage points; 95% CI, −1.2 to 2.6; P = .63). The 1-year cumulative probability of graft success was 96.5% (95% CI, 93.6%-98.9%) in the mild donor diabetes severity subgroup (n = 173) and 97.3% (95% CI, 95.4%-98.8%) in the moderate to severe donor diabetes severity subgroup (n = 336), using a diabetes severity rating scale based on medical history. The rates of primary donor failure, early failure related to surgical complications, and subsequent failure were as follows: 2.5% (23 of 912), 0.7% (6 of 912), and 0.3% (3 of 912), respectively, in recipients of tissue from a donor without diabetes, and 2.6% (13 of 509), 0.4% (2 of 509), and 0%, respectively, among recipients of tissue from a donor with diabetes. There were no failures due to graft rejection. Conclusions and Relevance The 1-year success rate in eyes undergoing DMEK with successfully prepared tissue was very high regardless of donor diabetes status. These results, supported by the separately reported finding that endothelial cell loss and cornea morphometry after 1 year were not affected by donor diabetes status, provide strong support for having no restrictions on the use of tissue from donors with diabetes for DMEK. Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Artificial intelligence in valvular heart disease: current evidence and future perspectives
Suc, Gaspard , Sengupta, Partho P. , Ali, Walid Ben , Piazza, Nicolò , Burwash, Ian G. , Theriault‐Lauzier, Pascal , Avram, Robert , Bruce, Charles J. , Bohbot, Yohann , Dreyfus, Julien , Enriquez‐Sarano, Maurice , Modine, Thomas , Messika–Zeitoun, David

Mayo Clinic

European Heart Journal - Valvular and Structural Heart Disease | September 8, 2025 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/ehjvshd/xwaf002 Get It

Abstract Valvular heart disease (VHD) is emerging as the next major epidemic in cardiovascular care, driven by the ageing population. The advent of less invasive alternatives to surgery—namely, transcatheter therapies—has revolutionized patient management, while simultaneously introducing new layers of complexity. Artificial intelligence (AI) holds significant promise to transform the care of patients with VHD across all dimensions, including diagnosis, prognostication, disease progression, and therapeutic decision-making. In this review, we provide a comprehensive overview of the current evidence, and discuss the challenges, risks, and future directions associated with the integration of AI in the management of VHD.